Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
Authors
Seung, KJKhan, P
Franke, MF
Ahmed, S
Aiylchiev, S
Alam, M
Putri, FA
Bastard, M
Docteur, W
Gottlieb, G
Hewison, C
Islam, S
Khachatryan, N
Kotrikadze, T
Khan, U
Kumsa, A
Lecca, L
Tassew, YM
Melikyan, N
Naing, YY
Oyewusi, L
Rich, M
Wanjala, S
Yedilbayev, A
Huerga, H
Mitnick, CD
endTB Study Group
Issue Date
2019-11-02Submitted date
2020-01-15
Metadata
Show full item recordJournal
Clinical Infectious DiseasesAbstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.Publisher
Oxford University PressPubMed ID
31676905Language
enDescription
We regret that this article is behind a paywall.ISSN
1537-6591ae974a485f413a2113503eed53cd6c53
10.1093/cid/ciz1084